141 related articles for article (PubMed ID: 37871379)
1. Combinations of radiotherapy with immunotherapy in nasopharyngeal carcinoma.
Yang X; Ren H; Li Z; Peng X; Fu J
Int Immunopharmacol; 2023 Dec; 125(Pt A):111094. PubMed ID: 37871379
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson L; Howard J; Gonzalez-Cruz J; Jackson C; Barnett C; Overton L; Liu H; Ladwa R; Simpson F; McGrath M; Wallwork B; Jones T; Ottensmeier C; Chua MLK; Perry C; Khanna R; Panizza B; Porceddu S; Lechner M
Int J Cancer; 2020 Apr; 146(8):2305-2314. PubMed ID: 31950498
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma.
Ma BBY; Chen YP; Hui EP; Liu X; Chan AKC; Chan ATC; Ma J
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-11. PubMed ID: 32191137
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
Huang H; Yao Y; Deng X; Huang Z; Chen Y; Wang Z; Hong H; Huang H; Lin T
Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37417358
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma.
Yeo ELL; Li YQ; Soo KC; Wee JTS; Chua MLK
Chin Clin Oncol; 2018 Apr; 7(2):15. PubMed ID: 29764160
[TBL] [Abstract][Full Text] [Related]
6. Future of Radiotherapy in Nasopharyngeal Carcinoma.
Sun XS; Li XY; Chen QY; Tang LQ; Mai HQ
Br J Radiol; 2019 Oct; 92(1102):20190209. PubMed ID: 31265322
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
[TBL] [Abstract][Full Text] [Related]
8. Five-year disease-free survival of Epstein-Barr virus-associated locoregionally advanced undifferentiated nasopharyngeal carcinoma patients treated with chemo-radiotherapy: a case report.
Wang N; Wang H; Jiang H; Bi Y; Zhao Y; He X; Cao F; Yuan Y
Ann Palliat Med; 2022 Mar; 11(3):1147-1152. PubMed ID: 35365045
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era.
Wang S; Chen S; Zhong Q; Liu Y
J Cancer Res Clin Oncol; 2023 May; 149(5):2071-2079. PubMed ID: 35876949
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic approaches in nasopharyngeal carcinoma.
Chow JC; Ngan RK; Cheung KM; Cho WC
Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
[No Abstract] [Full Text] [Related]
11. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
12. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH
Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467
[TBL] [Abstract][Full Text] [Related]
13. Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment.
Wang X; Zhang Y; Mu X; Tu CR; Chung Y; Tsao SW; Chan GC; Leung WH; Lau YL; Liu Y; Tu W
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35105688
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Cetuximab in Nasopharyngeal Carcinoma Patients Receiving Concurrent Cisplatin-Radiotherapy: A Meta-Analysis.
Wang L; Liu D; Wei D
Comput Math Methods Med; 2022; 2022():5145549. PubMed ID: 36060662
[TBL] [Abstract][Full Text] [Related]
16. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma.
Mané M; Benkhaled S; Dragan T; Paesmans M; Beauvois S; Lalami Y; Szturz P; Gaye PM; Vermorken JB; Van Gestel D
Oncologist; 2021 Jan; 26(1):e130-e141. PubMed ID: 32924198
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.
Hong M; Tang K; Qian J; Deng H; Zeng M; Zheng S; Ding K; Du Y; Sun R
Crit Rev Oncog; 2018; 23(3-4):219-234. PubMed ID: 30311576
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract][Full Text] [Related]
20. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
